Australia: Australian support laws clarified

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Australia: Australian support laws clarified

Australia has relatively recently implemented support laws that require a specification to provide sufficient information to enable the skilled person to perform an invention over the entire scope of the claims without undue burden or the need for further invention. These new support laws have been stringently applied by the Patent Office, in particular in relation to claims defining chemical compounds where, in many cases, the only claims considered to be enabled are ones directed to exemplified embodiments.

In Evolva SA [2017] APO 57 (14 November 2017) the Australian Patent Office considered the enablement of claims directed to polypeptides covered by at least 90% sequence identity to defined polypeptide sequences.

In determining whether the claims were enabled, the Delegate of the Patent Office considered the Explanatory Memorandum to the relevant support legislation as well as European and UK case law. Based on this, the Delegate settled on a two-step enquiry consistent with that taken under UK law.

The first stage involved determining whether the disclosure of the patent, read in the light of the common general knowledge of the skilled person, makes it plausible that the invention will work across the scope of the claim. If so, the second stage required consideration of whether the invention can be performed across the scope of the claim without undue burden.

The Delegate considered whether it was plausible that polypeptides which have as low as 90% identity would exhibit functional activity. In coming to a conclusion regarding the plausibility of the claims, the Delegate referred to a discussion in the specification regarding the manner in which functional polypeptide homologues may be generated. He also referred to the fact that conservative substitution of amino acids in polypeptides is widely practiced, and that the properties of the resulting variants can be predicted with some certainty, particularly where the active binding regions of the proteins are known. For these reasons, the Delegate found it plausible that the invention could be worked across the full scope of the claims.

In reaching a conclusion on the undue burden part of the enablement test, the Delegate found that the specification provided adequate guidance as to the manner in which polypeptide variants may be generated and tested; and that this did not present any apparent difficulties that would require the skilled person to undertake any prolonged research or experimentation that would be considered an undue effort. While the work to produce polypeptide variants could involve a reasonable degree of experimentation or trial and error, and even be time-consuming, the Delegate found that the nature of the work did not appear to constitute a research programme. Accordingly, the specification was found to meet the relevant enablement requirements.

This decision provides much-needed clarity regarding the test for determining enablement of chemical/protein and polypeptide claims and permits Examiners greater latitude for allowing claims directed to subject matter that goes beyond embodiments exemplified in the specification.

Grant Shoebridge


Shelston IPLevel 21, 60 Margaret StreetSydney NSW 2000, AustraliaTel: +61 2 9777 1111Fax: +61 2 9241 4666email@shelstonip.comwww.shelstonip.com

more from across site and SHARED ros bottom lb

More from across our site

The firm has taken the bold step of ditching the billable hour as its default pricing mechanism – watch now as rivals follow suit
The IP services provider is targeting further expansion as cost and efficiency pressures push law firms and in-house teams to rethink how they manage global portfolios
Two experienced UPC practitioners join the UK IP boutique’s growing German operation, with further recruitment planned as the firm expands in Europe
The Australian IP firm is taking on bigger rivals in Southeast Asia, betting that agility and transparent pricing can help it stand out
The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
Gift this article